Dietary modifications in patients receiving miglustat

Journal of Inherited Metabolic Disease

Volumn 33, Issue SUPPL. 3, 2010, Pages

  Champion, H ^a,d   Ramaswami, U ^a   Imrie, J ^b   Lachmann, R H ^c   Gallagher, J ^b   Cox, T M ^a   Wraith, J E ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 DEOXYNOJIRIMYCIN; CERAMIDE GLUCOSYLTRANSFERASE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSYLTRANSFERASE; LACTOSE; MIGLUSTAT;

ADOLESCENT; ADOLESCENT DEVELOPMENT; ADULT; AGE; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; CHILD DEVELOPMENT; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GASTROINTESTINAL DISEASE; HUMAN; LOW CARBOHYDRATE DIET; LYSOSOME STORAGE DISEASE; METABOLISM; MULTICENTER STUDY; RETROSPECTIVE STUDY; TIME; TREATMENT OUTCOME; UNITED KINGDOM; WEIGHT REDUCTION; YOUNG ADULT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; GASTROINTESTINAL DISEASES; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADOLESCENT DEVELOPMENT; ADULT; AGE FACTORS; CHILD; CHILD DEVELOPMENT; DIET, CARBOHYDRATE-RESTRICTED; ENGLAND; ENZYME INHIBITORS; GASTROINTESTINAL DISEASES; GLUCOSYLTRANSFERASES; HUMANS; LACTOSE; LYSOSOMAL STORAGE DISEASES, NERVOUS SYSTEM; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS; YOUNG ADULT;

EID: 84897927240     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-010-9193-4     Document Type: Article

References (10)

1. Aerts JM, Hollak CE, Boot RG, Groener JE, Maas M (2006) Substrate reduction therapy of glycosphingolipid storage disorders. J Inherit Metab Dis 29(2-3):449-456
2. Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B et al. (2003) The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis 26 (6):513-526
3. Elstein D, Hollak C, Aerts JM, van Weely S, Maas M, Cox TM et al. (2004) Sustained therapeutic effects of oral miglustat (Zavesca, N- butyldeoxynojirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 27(6):757-766
4. EMEA (2009) Miglustat (Zavesca®) summary of product characteristics. Retrieved 15 May, 2009, from http://www.emea.europa.eu/humandocs/PDFs/EPAR/ zavesca/H-435-PI-en.pdf
5. Ficicioglu C (2008) Review of miglustat for clinical management in Gaucher disease type 1. Ther Clin Risk Manage 4(2):1-7
6. Pastores GM, Barnett NL, Kolodny EH (2005) An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 27(8):1215-1227
7. Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6(9):765-772
8. Platt FM, Neises GR, Dwek RA, Butters TD (1994) Nbutyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 269(11):8362-8365
9. Platt FM, Jeyakumar M, Andersson U, Priestman DA, Dwek RA, Butters TD et al. (2001) Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy. J Inherit Metab Dis 24(2):275-290
10. Shapiro BE, Pastores GM, Gianutsos J, Luzy C, Kolodny EH (2009) Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment. Genet Med 11(6):425-433